Organization · Venture Capital
re.Mind Capital
re.Mind Capital is an early-stage venture capital firm focused on mental health and brain health, investing in innovative companies in areas such as psychedelic medicine and digital health platforms.
Overview
What re.Mind Capital does
What re.Mind Capital is
re.Mind Capital is an early-stage venture capital firm focused on mental health and brain health, investing in innovative companies in areas such as psychedelic medicine and digital health platforms.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2020
- Approximate age
- About 6 years
- Structured capabilities
- Funder
- Last reviewed
- May 1, 2026
Official channels
Find re.Mind Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
re.Mind Capital as a funder
Investment thesis
re.Mind Capital believes that mental and neurological health represents one of humanity's most prevalent and damaging problem areas. They invest in breakthroughs emerging from the convergence of neuroscience, pharmacology, digital health, AI, measurement, and brain-computer interfaces.
Focus narrative
The firm invests in early-stage companies that are pioneering solutions in mental health and brain health. Key focus areas include brain-computer interfaces, personalized treatment modalities, and novel pharmacological approaches. re.Mind Capital seeks to back science- and technology-led companies that have a clear path to clinical or therapeutic impact.
Value beyond capital
re.Mind Capital provides strategic support to its portfolio companies by leveraging the broader Apeiron network. The firm emphasizes a science-driven approach, offering insights and connections that can enhance clinical and therapeutic outcomes in mental and neurological health.
Focus and fit
- Stages
- Seed · Series A · Growth Equity
- Regions
- Global · North America · Europe
Availability
- Currently deploying
- Not published
Portfolio and track record
Portfolio context
Precision Neuroscience: A company focused on precision psychiatry and brain technology. Blackrock Neurotech: Innovators in next-generation brain-computer interfaces. Alto Neuroscience: A precision psychiatry company that recently secured $60M in financing. Synchron: Creators of the Stentrode, a non-invasive brain-computer interface. TRIPP: Offers immersive meditative experiences through XR technology. iLoF: Develops biomarker platforms using optical tweezers. Kanna Health: Focuses on novel therapeutics inspired by kanna. Bionaut Labs: Specializes in precision treatment using micro-robot delivery.
Common questions
What to know about re.Mind Capital
Upseed classifies re.Mind Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 1, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.